Sustained activation of Erk1/2 MAPK and cell growth suppression by the insert-negative, but not the insert-positive isoform of the human calcitonin receptor
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Recently we reported that calcitonin (CT) induces growth arrest at the G2 stage of the cell cycle in HEK-293 cell lines expressing the most abundant, insert-negative, isoform of the human CT receptor (insert -ve hCTR). The present study investigates the involvement of the MAPK signalling pathway in the anti-proliferative actions of CT and compares the activity of an isoform of the hCTR that contains a 16 amino acid insert in the first putative intracellular loop (insert +ve hCTR). Comparison of HEK-293 cells stably transfected with the insert -ve or the insert +ve hCTR, showed that accumulation of cAMP and intracellular free calcium in response to CT were specific for the insert -ve receptor isoform. However, a novel acidification of the extracellular medium was mediated by both isoforms. Treatment with CT of cells expressing the insert -ve hCTR, caused a decrease in cell growth associated with an induction of p21(WAF1/CIP1). Analysis by fluorescence-activated cell scanning showed that growth inhibition was associated with an accumulation of cells in G2. CT treatment of cells expressing the insert -ve, but not insert +ve hCTR, induced the phosphorylation of Erk1/2 MAPK, which persisted for at least 72 h. Treatment of cells expressing the insert -ve hCTR with the MAPK kinase (MEK) inhibitor, PD-98059, inhibited the phosphorylation of Erk1/2 and abrogated the growth inhibitory effects of salmon CT, the accumulation of cells in G2, and the associated induction of p21(WAF1/CIP1). These data suggest that activation of Erk1/2 are downstream effectors of the insert -ve hCTR in modulating cell cycle progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcitonin alters behaviour of isolated osteoclasts
Chambers, T. J., & Magnus, C. J. (1982) · The Journal of Pathology · doi:10.1002/path.1711360104 · Cited by 504
Cloning and characterization of an abundant subtype of the human calcitonin receptor.
Kuestner, R. E., Elrod, R. D., Grant, F. J., Hagen, F. S., Kuijper, J. L., Matthewes, S. L., O'Hara, P. J., Sheppard, P. O., Stroop, S. D., & Thompson, D. L. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09678-6 · Cited by 149
Gorn, A. H., Rudolph, S. M., Flannery, M. R., Morton, C. C., Weremowicz, S., Wang, T. Z., Krane, S. M., & Goldring, S. R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117970 · Cited by 100 · cited 3×
“When expressed in a number of cell types the insert +ve receptor isoform displays similar affinity for CT as the insert ve variant (Nussenzveig et al. 1994, Albrandt et al. 1995, Gorn et al. 1995, Moore et al. 1995) but has markedly altered G-protein coupling efficiency ( Gorn et al. 1995, Moore et al. 1995).”
BackgroundAlbrandt, K., Brady, E. M., Moore, C. X., Mull, E., Sierzega, M. E., & Beaumont, K. (1995) · Endocrinology · doi:10.1210/endo.136.12.7588285 · Cited by 88
Cited by
Forty years of calcitonin—where are we now? A tribute to the work of Iain Macintyre, FRS
Zaidi, M., Inzerillo, A. M., Moonga, B. S., Bevis, P. J. R., & Huang, C. L.-H. (2002) · Bone · doi:10.1016/s8756-3282(02)00688-9 · Cited by 151
Morfis, M., Tilakaratne, N., Furness, S. G. B., Christopoulos, G., Werry, T. D., Christopoulos, A., & Sexton, P. M. (2008) · Endocrinology · doi:10.1210/en.2007-1735 · Cited by 134
Calcitonin: Physiology or fantasy?
Davey, R. A., & Findlay, D. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1869 · Cited by 101
Self-citationFindlay, D. M., Sexton, P. M., & Martin, T. J. (2016) · Endocrinology: Adult and Pediatric · doi:10.1016/b978-0-323-18907-1.00058-5 · Cited by 2
Self-citation
Metadata
- Authors
- Raggatt, L., Evdokiou, A., & Findlay, D.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2000-10-01
- Volume
- 167
- Issue
- 1
- Pages
- 93-105
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2112842500
- Cited by
- 29
- References
- 4
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.